Background: Prior work suggests some individual immunomarkers may be useful moderators of treatment response between antidepressant medications. The relative moderating effect of individual immunomarkers remains unclear. It is also unknown whether combinations of immunomarkers have a superior moderating effect compared to any individual immunomarker.
Methods: Baseline immunomarker levels were assayed using multiplex from a subset of participants in the CO-MED trial (n = 143). Individual and combinations of 19 immunomarkers were modeled as moderators between the three treatment arms (escitalopram monotherapy, escitalopram-bupropion and venlafaxine-mirtazapine) across a variety of depression outcomes.
Results: Only IL-13 demonstrated a consistent moderating effect across all depression outcome measures. High IL-13 (>20 pg/ml) was associated with higher remission rates to bupropion-escitalopram (67%) versus escitalopram (24%) whereas low IL-13 was associated higher remission rates to escitalopram (59%) versus bupropion-escitalopram (38%). A similar, but weaker moderating effect was observed with venlafaxine-mirtazapine versus escitalopram. The addition of multiple immunomarkers did not consistently improve predictive modeling.
Limitations: This is a secondary analysis of a single clinical trial with a relatively small sample size per treatment arm. The testing of specific individual and combinations of biomarkers was data-driven.
Conclusions: Among 19 immunomarkers, Il-13 was the best single moderator of treatment outcome. Combinations of immunomarkers were not meaningfully superior to Il-13.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2021.08.116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Visnagin alleviates rheumatoid arthritis via its potential inhibitory impact on malate dehydrogenase enzyme: in silico, in vitro, and in vivo studies.
Genes Nutr
October 2024
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Article Synopsis
- - Rheumatoid arthritis (RA) is a long-term autoimmune disorder, and this study explores how visnagin can hinder malate dehydrogenase (MDH) activity and enhance the anti-inflammatory effects when paired with methotrexate in a rat model.
- - The research involved various methods such as molecular docking and assessing specific inflammatory markers (like TNF-α and IL-6) to evaluate visnagin's effectiveness.
- - Findings indicate that visnagin not only inhibits MDH but also promotes anti-inflammatory T cells and reduces inflammatory cytokines, showcasing its potential as a treatment to improve RA outcomes alongside methotrexate.
Therapeutic and immunomodulatory effects of Bojungikki-tang on cancer: a scoping review.
BMC Cancer
September 2024
KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672, Yuseong-Daero, Yuseong-Gu, Daejeon, 34054, Republic of Korea.
Background: Cancer remains a major global health concern, with conventional treatments often limited by side effects and resistance. Bojungikki-tang (BJIKT), a traditional herbal formula, has shown promise in alleviating cancer-related symptoms and enhancing anti-cancer effects when combined with conventional treatments. As immune checkpoint inhibitors (ICIs) have become the standard for cancer treatment, a combination of BJIKT and ICIs may exhibit immune-mediated anti-cancer effects.
View Article and Find Full Text PDFApplication of Aptamer-SERS Nanotags for Unveiling the PD-L1 Immunomarker Progression Correlated to the Cell Metabolic Bioprocess.
Anal Chem
April 2024
CAS Key Laboratory of Ion-Beam Bioengineering, Institute of Intelligent Machines, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China.
In recent years, the expression and progression of programmed cell death ligand 1 (PD-L1) as an immunomarker in the context of a cell metabolic environment has gained significant attention in cancer research. However, intercellular bioprocesses that control the dynamics of PD-L1 have been largely unexplored. This study aimed to explore the cell metabolic states and conditions that govern dynamic variations of PD-L1 within the cell metabolic environment using an aptamer-based surface-enhanced Raman scattering (SERS) approach.
View Article and Find Full Text PDFCase report: Intraneural perineurioma in dogs: a case series and brief literature review.
Front Vet Sci
January 2024
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Intraneural perineurioma is an exceptionally rare neoplasm in animals. This case study comprises a series of three cases and a brief literature review focusing on canine intraneural perineurioma. The pathological and immunohistochemical findings are documented, revealing that canine intraneural perineurioma frequently affects adult dogs aged between 3 and 10 years old, with a male predominance.
View Article and Find Full Text PDFmicroRNA hsa-miR-425-5p and hsa-miR-4523 expressions as biomarkers of active pulmonary tuberculosis, latent tuberculosis infection, and lymph node tuberculosis.
Noncoding RNA Res
December 2023
Hasanuddin University Medical Research Center Laboratory, Faculty of Medicine, Universitas Hasanuddin, Makassar, 90245, South Sulawesi, Indonesia.
Background: Studies on miRNA highlight its significance as an immunomarker for several diseases, including tuberculosis. This study aimed to determine the difference between miR-425-5p and miR-4523 expressions in patients with active pulmonary TB (PTB), latent TB infection (LTBI), and lymph node TB (LNTB), whose diagnosis remains challenging.
Methods: This case-control study was performed on blood samples obtained from 23 patients with PTB, 21 with LTBI, 21 with LNTB, and 25 healthy controls (HC).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!